Anthrax inhalation presents with a symptom.
 All currently used anthrax vaccines show considerable local and general reactogenicity (erythema, induration, soreness, fever) and serious adverse reactions occur in about 1% of recipients
Before 2001, fatality rates for inhalation anthrax were 90%; since then, they have fallen to 45%

